Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.
about
Update on rational targeted therapy in AMLThe Interplay of Reactive Oxygen Species, Hypoxia, Inflammation, and Sirtuins in Cancer Initiation and ProgressionOncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsCurrent and future molecular profiling of cancer by next-generation sequencingPreclinical mouse cancer models: a maze of opportunities and challenges.Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and TreatmentTargeting substrate-site in Jak2 kinase prevents emergence of genetic resistanceTargeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies.Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.CRISPR/Cas9: From Genome Engineering to Cancer Drug DiscoveryA DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivoUSP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer.Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapAA liaison between mTOR signaling, ribosome biogenesis and cancerMonocytes promote liver carcinogenesis in an oncogene-specific manner.ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.Biocomputing drug repurposing toward targeted therapies.FLT3 inhibitors: clinical potential in acute myeloid leukemia.Suppression of gain-of-function mutant p53 with metabolic inhibitors reduces tumor growth in vivo.Targeting tumor suppressor genes for cancer therapy.Informatics Approaches for Predicting, Understanding, and Testing Cancer Drug Combinations.Synthetic lethality and cancer.ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology.TetraMabs: simultaneous targeting of four oncogenic receptor tyrosine kinases for tumor growth inhibition in heterogeneous tumor cell populations.A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication.Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy.The cancer cell adhesion resistome: mechanisms, targeting and translational approaches.Transcriptional Addiction in Cancer.Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System.Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours.Wnt signalling is a bi-directional vulnerability of cancer cells.Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways.Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers.Target Discovery for Precision Medicine Using High-Throughput Genome Engineering.Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.
P2860
Q26766152-16E31E3C-5E6E-44C9-AF7A-ED22569A1B61Q26769965-3D81257A-F1A7-4038-9A01-D48556AACA4BQ26774625-B13348F2-A24E-4E15-9E82-E3B00568FD96Q26796272-FF3521E1-EA5B-422F-923B-46EC84EFC1B1Q27322080-D3CD39C2-B9E6-4B72-96C1-2D041E9ECF6CQ28076462-361BAD95-5E52-4DB7-96C3-C4B0FEA2D38BQ30666276-0A2BED1C-8A50-44CD-BEA8-7DEBFD170CE1Q33591876-262E6048-D696-45AB-B27D-B0798D9BA537Q33709971-2F05D280-F879-4156-B2C5-BC74FFA0A9F5Q33772342-3D000DE3-60B6-4AD6-BF99-A7892BBBD492Q34491149-4A7F6C2B-2FCA-489F-984B-8CBFFE156CD7Q36268425-6FE68B4D-2CE5-4BB3-966F-2E8924ABE0FBQ36545083-7A281727-C267-4388-8CF6-4369FD645E2EQ36615429-2D28759B-DCE7-4A58-8939-8585257E0D85Q36706259-5B8F4A2B-49BE-4E29-BBE3-0EAFC33B701AQ37379680-9960CAA3-AB14-441F-BEAC-DBE10C196403Q37538158-64F610B9-5385-44F0-8349-CF974FF767C7Q37638749-86DBD87C-E5E9-4180-9B0B-AC8EE94EDFEFQ37718416-D1F2E361-84A3-4AB3-88C6-C43B82E93E4AQ38601568-BD30CADB-F264-4A83-A389-5B6247E51053Q38668684-48923EE3-3316-4CD4-AAD8-599080C70E7CQ38709651-27E35A03-9BFA-4B48-852D-38C415BCF22CQ38729111-82AF39CC-3291-4935-AE98-A2934089BDF3Q38748906-B5552B91-B289-4277-8CBD-BC868A6E66EFQ38812797-8AB3C9A4-E147-4F0D-8BBD-BFA0308E39ADQ38844605-35AD22F1-AB71-4CDB-AE37-9803DCC00F07Q38893850-41187393-D53E-402B-A5E3-2F356C51A506Q38935571-83FB1AA7-5F07-44D2-A73D-C0FE64E61695Q39046463-646D12F1-B50E-45E5-8CA5-207C809CC10CQ39130428-DE61D9D4-1253-4B83-A251-87753EE5A086Q39176607-2F06058B-77D6-4B5D-A6AE-F00EFF753A51Q39329582-86984086-E9F4-47C4-A8E2-90A8E37C8066Q41035560-A2583F20-7FA5-434F-9364-7A49FAE59BCEQ41896783-98F979DA-53E3-48FA-9369-E1C29F335F95Q42321100-DF6CBF60-BB1A-4C57-82ED-651DF20640E9Q42338790-D2092A86-932C-4E45-82DD-598E9B218227Q44502910-524A7443-26EF-4FCA-8FA3-BB7BB2BA1259Q47100164-19925260-C06E-41CF-A683-BEDAFCB07CF7Q47356354-0B502CAB-E675-4416-93E8-6C880F686F35Q47581752-650E4DD5-776F-420F-898E-098BA00D54B3
P2860
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Oncogene addiction: pathways o ...... , and road maps toward a cure.
@en
type
label
Oncogene addiction: pathways o ...... , and road maps toward a cure.
@en
prefLabel
Oncogene addiction: pathways o ...... , and road maps toward a cure.
@en
P2093
P2860
P356
P1433
P1476
Oncogene addiction: pathways o ...... , and road maps toward a cure.
@en
P2093
Raymond Pagliarini
Wenlin Shao
William R Sellers
P2860
P304
P356
10.15252/EMBR.201439949
P577
2015-02-13T00:00:00Z